

# **One Application. Complete Resolution.**



An advanced human acellular dermal matrix (ADM) trusted globally



# An Advanced Healing Solution for Complex Wounds

Dermacell AWM® is a state-of-the-art human acellular dermal matrix (ADM) engineered to repair and reinforce damaged or inadequate soft tissue in even the most challenging wound care and surgical cases.<sup>1</sup> Powered by LifeNet Health's proprietary Matracell® decellularization technology, it retains essential biologics components that create an optimal environment to support healing.<sup>2-6</sup>





*Dermacell AWM® retains essential ECM components that are vital for tissue repair and wound healing.<sup>2, 3, 5, 6</sup>*

Dermacell AWM® has demonstrated effectiveness across a wide range of applications<sup>4, 9</sup> - from chronic ulcers and traumatic injuries to complex surgical reconstruction. Its advanced acellular dermal matrix provides a supportive scaffold that aids in tissue regeneration and accelerates healing. Unlike many alternatives, it can be applied to non-healing wounds, even those with exposed tendon or bone.<sup>4</sup> This combination of biologic activity, structural integrity, and clinical versatility makes Dermacell AWM® a trusted solution for advanced wound care.

## Technology That Delivers

At the core of Dermacell AWM®'s performance is Matracell® Technology - LifeNet Health's proprietary decellularization process that enhances both safety and efficacy of allograft tissues. By removing the vast majority of donor DNA<sup>2</sup>, Matracell minimizes the risk of immune response while preserving the extracellular matrix (ECM), including key structural proteins and bioactive elements.<sup>2, 3, 5, 6</sup> This balance supports optimal cell attachment, migration, and vascularization - accelerating healing while maintaining biomechanical strength. Widely used across surgical applications, Matracell® ensures a high-quality, biocompatible graft for advanced tissue repair.




*Preserving Biomechanical Integrity for Reliable Surgical Use  
Maintains tensile strength and suture pull-out performance - comparable to fresh dermis<sup>5, 6</sup>*

Dermacell AWM is indicated for homologous use for the replacement of damaged skin due to diabetic foot ulcers, venous leg ulcers, dehisced surgical wounds, and traumatic burns.<sup>1</sup>

# The Power of ECM in Dermacell AWM

Thanks to its proprietary technology, Dermacell AWM® retains all the essential extracellular matrix (ECM) components – such as collagen, elastin, matrikines, growth factors, and cytokines – that are critical to promote cellular infiltration, vascularization, and tissue remodeling.<sup>2, 3, 5, 6</sup>

<b>Collagen</b>	Supports cell migration, proliferation, matrix remodeling, and angiogenesis. <sup>3, 9-11</sup> It contains 16 types of human collagen, primarily Type I and III, in the same ratio as native dermis. <sup>5, 6</sup>
<b>Binding Proteins</b>	Maintain tissue stability and facilitate reconstructive remodeling. <sup>13</sup>
<b>Other ECM Proteins</b>	Rich in Elastin, Nidogen (Entactin), and Keratin, which contribute to tissue strength and repair. <sup>5, 14-17</sup>
<b>Matrikines</b>	Retains matrikines. <sup>5, 18-20</sup>
<b>Growth Factors</b>	Retains BMP6, EGF, HGF, VEGFA, and PDGF-D. <sup>5, 21-23</sup>
<b>Cytokines</b>	Retains cytokines consistent. <sup>5, 6, 21, 23, 24</sup>




\*Data on File at LifeNet health: NPR 05-013

By preserving the ECM's native structure, Dermacell AWM® delivers a comprehensive healing solution, mimicking healthy human skin and supporting the body's natural healing process.<sup>5, 6</sup>

## Proven Performance in Every Stage of Wound Healing

Dermacell AWM® is backed by strong clinical evidence, including its pivotal role in the largest randomized controlled trial involving human acellular dermal matrix (ADM) for chronic wounds.<sup>9</sup> Peer-reviewed studies consistently demonstrate its effectiveness across a range of wound types and severities, including all Wagner grades—from early-state ulcers to deep, complex wounds.<sup>4, 9</sup> With its strong clinical foundation and proven outcomes, Dermacell AWM® continues to set a high standard in the field of wound healing and tissue regeneration, making it a trusted choice in advanced wound care.



With Dermacell AWM, safety and simplicity come standard—ensuring confidence in every application.

# Versatile. Reliable. Effective.

Dermacell AWM® offers broad clinical utility across a wide range of applications - from chronic wounds and traumatic injuries to complex surgical reconstruction.<sup>1</sup> Its advanced acellular structure creates an ideal environment for tissue regeneration, even in challenging cases with exposed tendon or bone.<sup>9</sup> By preserving key extracellular matrix (ECM) components, Dermacell AWM® promotes cellular infiltration, vascularization, and tissue remodeling, accelerating healing where it's needed most.<sup>2,3,5,6</sup> With its versatility and proven clinical performance, it's a trusted solution for healthcare professionals seeking safe, effective, and reliable wound care.

## Chronic Wounds (Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Injury)

### Diabetic Foot Ulcer<sup>4</sup>



Presentation



15 weeks

Courtesy of Zakee Shabazz, DPM, FACFAS

### Venous Ulcers



Presentation



9 weeks

Courtesy of Zakee Shabazz, DPM, FACFAS

### Pressure Ulcer



Presentation



Dermacell AWM  
70-Days Post-Op

Courtesy of Dr. Sabaya

## Trauma (Traumatic Injury, Burns, Dehiscence)

### Degloving Injury



Presentation



12 weeks

Courtesy of Zakee Shabazz, DPM, FACFAS

### Surgical Dehiscence



Presentation



8 weeks



Presentation



8 weeks

Courtesy of Zakee Shabazz, DPM, FACFAS

### Burns<sup>28</sup>



Presentation



6 Month

Courtesy of Zakee Shabazz, DPM, FACFAS

## Surgical Reconstruction (Craniomaxillofacial, Chronic Scalp Wound, Mohs Procedure, Soft Tissue Reconstruction)

### Stage IIB Melanoma<sup>29</sup>



Presentation



8 weeks

Courtesy of Zakee Shabazz, DPM, FACFAS

### Surgical Reconstruction



Preoperative



15 Weeks Postoperative

Courtesy of Dr. Bertasi, Italy

# Confidence in Every Application

Dermacell AWM gives surgeons the confidence of a safe, sterile, and ready-to-use allograft - with the essential components for wound healing<sup>5,6</sup> - improving efficiency without ever compromising on quality. This is what it means to give healing every advantage.

# Unmatched Safety & Convenience

Dermacell AWM® is engineered for maximum safety and surgical efficiency — delivering a biologic solution clinicians can trust, exactly when they need it.<sup>1-3, 27</sup>

Proven Safety Profile	Ready-to-Use Convenience
Validated removal of donor cells and cellular components <sup>1</sup>	Stored at room temperature with no refrigeration or freezing required
Validated medical device-grade sterility (SAL 10-6) <sup>1</sup>	Ready to use straight from the package with no rehydration required
Validated viral inactivation <sup>27</sup>	Available in both meshed and unmensed configurations and a wide range of sizes to fit diverse clinical needs

With Dermacell AWM, safety and simplicity come standard - ensuring confidence in every application.

## One Application. Two Distinct Sides for Targeted Healing.

Dermacell AWM offers two distinct sides, each with unique properties to enhance tissue integration and wound recovery.

*Clinical Tip: When applied, the reticular side should be placed against the surgical wound or the most vascularized tissue to promote healing.*

DermACELL AWM® Advanced Decellularized Dermis					
	THICKNESS	SIZE	SHELF LIFE	ORDER CODE	STORAGE
 Unmeshed	0.2 - 1.00 mm	2 x 2 cm	3 years	DCELL100	ROOM TEMPERATURE Ready-to-use (15°C to 30°C)
 Meshed Meshed at a 1.5:1 ratio		4 x 4 cm	3 years	DCELL101	
		5 x 7 cm	3 years	DCELL102	
		6 x 7 cm	3 years	DCELL103	
		4 x 8 cm	3 years	DCELL104	
		2 x 2 cm	3 years	DCELL110	
		3 x 3 cm	3 years	DCELL111	
		4 x 4 cm	3 years	DCELL112	
		5 x 7 cm	3 years	DCELL152	
		6 x 7 cm	3 years	DCELL153	
		4 x 8 cm	3 years	DCELL154	
		5 x 9 cm	3 years	DCELL155	

# A Global Leader in Regenerative Medicine

LifeNet Health is a nonprofit, mission-driven leader in regenerative medicine, committed to saving lives, restoring health, and giving hope through innovative bio-implant solutions. With more than 40 years of expertise, we set the standard in tissue processing, research, and ethical donation practices. Our global mission extends to India, where we support clinicians with advanced, high-quality wound care and surgical solutions. By prioritizing safety, accessibility, and innovation, LifeNet Health is helping to meet India's evolving healthcare needs — while delivering trusted solutions that improve patient outcomes worldwide.



**With more than 20,000 allografts distributed in 23 countries from the US, Latin America, Europe, Middle East, India, and Asia, Dermacell AWM® gives healing every advantage.**

## References

1. Data on file at LifeNet Health. Dermacell Instructions for Use, 63-0050-05-EN
2. Moore MA, Samsell B, Wallis G, et al. Decellularization of human dermis using non-denaturing anionic detergent and endonuclease: a review. *Cell Tissue Bank.* 2015; 16(2):249-259. <https://doi.org/10.1007/s10561-014-9467-4>
3. Agrawal H, Tholpady SS, Capito AE, Drake DB, Katz AJ. Macrophage phenotypes correspond with remodeling outcomes of various acellular dermal matrices. *Open Journal of Regenerative Medicine.* 2012; 01(03):51-59. <https://doi.org/10.4236/ojrm.20123008>
4. Cazzell S, Moyer PM, Samsell B, Dorsch K, McLean J, Moore MA. A Prospective, Multicenter, Single-Arm Clinical Trial for Treatment of Complex Diabetic Foot Ulcers with Deep Exposure Using Acellular Dermal Matrix. *Adv Skin Wound Care.* 2019 Sep;32(9):409-415. doi: 10.1097/01.ASW.0000569132.38449.c0. PMID: 31361269; PMCID: PMC7328871. 68-20-047, Analysis of the Acellular Matrix, Growth Factors, and Cytokines Present in Oracell.
5. LifeNet Health, TR 0292, LifeNet Health's Decellularized Dermis, Dermacell, Comparison to the USP Monograph, Scaffold Human Dermis.
6. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. *Diabetes Care.* 1998 May;21(5):855-9.
7. Frykberg RG, Gibbons GW, Walters JL, Wukich DK, Milstein FC. A prospective, multicenter, open-label, single-arm clinical trial for treatment of chronic complex diabetic foot wounds with exposed tendon and/or bone: positive clinical outcomes of viable cryopreserved human placental membrane. *Int Wound J.* 2017 Jun;14(3):569-577.
8. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. *Wound Repair and Regeneration.* 2017.
9. Ricard-Blum, S. (2011). Collagen family of proteins. *Glycobiology.* 21(2), 181-197. Link to article "The Role of Collagen in Skin Wound Healing"
10. Rodrigues, M., Kosaric, N., Bonham, C. A., & Gurtner, G. C. (2019). Wound Healing: A Cellular Perspective. *Physiological Reviews.* 99(1), 665-706. Link to article "In Vitro Models for Skin Regeneration and Collagen's Role"
11. Shevchenko, R. V., James, S. L., & James, S. E. (2010). A review of tissue-engineered skin bioconstructs available for skin reconstruction. *Journal of the Royal Society Interface.* 7(43), 229-258. Link to article
12. Schultz, G. S., & Wysocki, A. (2009). Interactions between extracellular matrix and growth factors in wound healing. *Wound Repair and Regeneration.* 17(2), 153-162.
13. Debelli, L., & Tamburro, A. M. (1999). Elastin: molecular description and function. *International Journal of Biochemistry & Cell Biology.* 31(2), 261-272. Link to article "Elastin-derived peptides: biological effects and potential therapeutic applications"
14. Brassart, B., Randoux, A., Hornebeck, W., & Emonard, H. (1998). Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane type-1 MMP (MT1-MMP), and tissue inhibitor of metalloproteinases-2 by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. *Cancer Research.* 58(22), 5287-5292. Link to article Nidogen (Entactin) "Nidogens: biological roles and structure-function relationships"
15. Ho, M. S., Böse, K., Mokkpati, S., Nischt, R., & Smyth, N. (2008). Nidogens – extracellular matrix linker molecules. *Microscopy Research and Technique.* 71(5), 387-395. Link to article "Nidogen: a key molecule in basement membrane assembly"
16. Fox, J.W., Mayer, U., Nischt, R., Aumailley, M., Reinhardt, D., Wiedemann, H., Mann, K., Timpl, R., Krieg, T., Engel, J., et al. (1991). Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. *EMBO J.* 10, 3137-3146.
17. Maquart, F. X., Bellon, G., Pasco, S., & Monboisse, J. C. (2005). Matrikines in the regulation of extracellular matrix degradation. *Biochimie.* 87(3-4), 353-360. Link to article "Role of Matrikines in Tissue Repair"
18. Ricard-Blum, S., & Ballut, L. (2011). Matriacravins derived from collagens and proteoglycans. *Frontiers in Bioscience.* 16, 674-697. Link to article "Matrikines and Wound Healing"
19. Gelse, K., Poschl, E., & Aigner, T. (2003). Collagens—structure, function, and biosynthesis. *Advanced Drug Delivery Reviews.* 55(12), 1531-1546.
20. Barrientos, S., Stojadinovic, O., Golinko, M. S., Brem, H., & Tomic-Canic, M. (2008). Growth factors and cytokines in wound healing. *Wound Repair and Regeneration.* 16(5), 585-601. Link to article "The Role of Growth Factors in Wound Healing"
21. Werner, S., & Grose, R. (2003). Regulation of wound healing by growth factors and cytokines. *Physiological Reviews.* 83(3), 835-870. Link to article "Mechanisms of Growth Factor Action in Wound Healing"
22. Eming, S. A., Krieg, T., & Davidson, J. M. (2007). Inflammation in wound repair: molecular and cellular mechanisms. *The Journal of Investigative Dermatology.* 127(3), 514-525.
23. Gillitzer, R., & Goebeler, M. (2001). Chemokines in cutaneous wound healing. *Journal of Leukocyte Biology.* 69(4), 513-521.
24. Management in Comparison with Advanced Moist Wound Therapy. *Pafmj.* 2021; 71(6):2087-2090. <https://doi.org/10.51253/pafmj.v6i6.6231>
25. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. *Diabetes Care.* 2008; 31(4):631-636. <https://doi.org/10.2337/dc07-2196>
26. Moore MA. Inactivation of enveloped and non-enveloped viruses on seeded human tissues by gamma irradiation. *Cell Tissue Bank.* 2012 Aug;13(3):401-7. doi: 10.1007/s10561-011-9266-0.
27. Chen SG, Tzeng YS, Wang CH. Treatment of severe burn with DermACELL®, an acellular dermal matrix. *Int J Burns Trauma.* 2012; 2(2): 105-109
28. On File with LifeNet Health: 68-20-195

